Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFX16H)

• Drug Name: Iso-OMPA Drug Info
• Synonyms: iso-OMPA; tetraisopropyl pyrophosphoramide; 513-00-8; TETRAISOPROPYLPYROPHOSPHAMIDE; Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)-; Tetraisopropylpyrophosphoramide; MLS002153308; CHEMBL494887; EINECS 208-149-5; Tetra(monoisopropyl)pyrophosphortetramide; N,N',N'',N'''-Tetraisopropyldiphosphoramide; n,n'-diisopropylphosphorodiamidic anhydride; AC1L1KBH; Lopac-T-1505; Lopac0_001184; Tetraisoproryl Pyrophosphoramide; AC1Q6T49; SCHEMBL6263949; Tetraisopropyl pyrophos-phoramide; IOIMDJXKIMCMIG-UHFFFAOYSA-; BDBM10625

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5420
  CAS Number: CAS 513-00-8
  TTD Drug ID: DMFX16H

Molecule-Related Drug Atlas

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[3]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[4]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[5]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[6]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[7]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[8]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[9]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[10]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[11]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[12]

Drug(s) Targeting Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hexafluronium bromide	DMFY307	Spasm	MB47.3	Approved	[13]
MEPTAZINOL	DMPSB8F	Pain	MG30-MG3Z	Approved	[14]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[15]
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[16]
Plasma derived human butyrylcholinesterase	DMF3IBC	Neurotoxicity	NE61	Phase 1	[17]
Protexia	DME1Y9W	Alzheimer disease	8A20	Phase 1	[18]
JES-9501	DMYR3IE	Alzheimer disease	8A20	Phase 1	[19]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[20]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[20]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[20]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[21]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[22]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[23]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[24]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[25]
Succinylcholine	DM2ET1M	Plasma cell myeloma	2A83.1	Approved	[26]
Ethopropazine	DM0N3L7	Parkinson disease	8A00.0	Approved	[22]
Dimenhydrinate	DM264B3	Meniere disease	AB31.0	Approved	[27]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[28]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[1]
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[2]

References

• [1] Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
• [2] Phenyl valerate esterase activity of human butyrylcholinesterase. Arch Toxicol. 2017 Oct;91(10):3295-3305.
• [3] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [5] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [6] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [7] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [8] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [10] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [11] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [12] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [13] Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
• [14] Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
• [15] Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
• [16] Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
• [17] Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
• [18] In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
• [19] Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
• [20] A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
• [21] Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
• [22] Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
• [23] Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
• [24] Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
• [25] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [26] Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
• [27] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [28] Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.